Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solanezumab
Biotech
Lilly's 10-year bet on pre-symptom Alzheimer's ends in failure
Lilly began the trial in 2013 to test solanezumab in people who had amyloid plaque accumulation in the brain but were yet to develop symptoms.
Nick Paul Taylor
Mar 9, 2023 9:35am
Roche refreshingly cautious on Alzheimer's hopeful gantenerumab
Feb 5, 2021 7:55am
Lilly and Roche's antibodies fail late-phase Alzheimer's test
Feb 10, 2020 6:51am
Analysts on amyloid thesis: It's not dead yet
Dec 9, 2016 4:51am
Lilly gives up on Alzheimer's hope solanezumab
Nov 23, 2016 8:08am
Alzheimer’s biotech Alzheon to move once-failed drug into new PhIII
Jul 25, 2016 9:30am
